| Document |
Document Title |
|
WO/2024/057304A1 |
The present disclosure generally relates to terpene -based vesicular delivery systems that are substantially phospholipid-free, and which are suitable for dermal and/or transdermal applications. The compositions provided by the invention...
|
|
WO/2024/059169A1 |
The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2024/056075A1 |
Disclosed in the present invention is the use of a reagent for detecting the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing glioma in a subject, wherein the level of DDR2 in a sample fro...
|
|
WO/2024/059183A1 |
Provided herein are methods of treating cancer in a subject, the method comprising administering to the subject an agent that increases or stabilizes the activity or expression of PIEZO 1.
|
|
WO/2024/058427A1 |
A composition containing a steroid compound and a ginseng extract selected from the group consisting of a ginseng extract, a red ginseng extract, and a black ginseng extract as active ingredients provided by the present invention has a w...
|
|
WO/2024/057193A1 |
The present invention relates to crystalline forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) salts or cocrystals, as well as compositions, methods of preparation and methods of their use. The present invention also relates to said c...
|
|
WO/2024/056077A1 |
Provided herein are compounds, pharmaceutical compositions, and methods for binding or modulating a DDB1-and CUL4-associated factor 1 (DCAF1) protein. In some aspects, the compound induces proteasomal degradation of a target protein.
|
|
WO/2024/058193A1 |
The present invention addresses the problem of providing a composition for an external preparation for skin, the composition: containing an ester-based steroid and gamma oryzanol, both the ester-based steroid component and the gamma oryz...
|
|
WO/2024/055810A1 |
Use of 6-phosphogluconic acid and a derivative thereof in preparing a medicament for preventing or treating glycometabolism disorder diseases. The 6-phosphogluconic acid and the derivative thereof are a type of cell glycometabolism regul...
|
|
WO/2024/055112A1 |
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...
|
|
WO/2023/213211A9 |
Disclosed herein is a 2,4-disubstituted-5-fluoropyrimidine derivative having a structural general formula represented by formula I: wherein, R1 and R2 are each independently selected from: R4 is selected from: Also disclosed herein is a ...
|
|
WO/2024/059353A1 |
This disclosure describes compositions including cannabinoids and omega fatty acids and methods of using those compositions including, for example, to treat or prevent inflammation, as an immunosuppressant, and/or as an anti-cancer thera...
|
|
WO/2024/056642A1 |
The present invention relates to a pharmaceutical composition in the form of a transdermal patch comprising aminophylline or theophylline for use in the treatment or prevention of a hypomyelinating or a demyelinating disease or condition...
|
|
WO/2024/056091A1 |
The present invention relates to a pyridonopyrimidine derivative as an RSK protein kinase inhibitor and use thereof. Specifically, the present invention relates to a compound represented by formula I, a pharmaceutical composition compris...
|
|
WO/2024/059471A2 |
Described herein is the development of ureas and thioureas as small molecular weight fortilin inhibitors. Small molecular weight compounds that inhibit fortilin, as well as compositions, and methods for using same, described herein ameli...
|
|
WO/2024/059864A2 |
The present disclosure provides novel large serine recombinases and their cognate attachment sites in the human genome. Methods for using these large serine recombinases and attachment sites are also provided herein.
|
|
WO/2024/059842A2 |
Pharmaceutical formulations for nasal administration are disclosed. The pharmaceutical formulation contains a green tea catechin derivative (such as an epigallocatechin-3-gallate-palmitate); and preferably further includes a carbohydrate...
|
|
WO/2024/059017A2 |
The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are prov...
|
|
WO/2024/056631A1 |
The present invention relates to a S1P1 receptor modulator, or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of a type 1 interferon mediated disease in a subject that has a high type 1 interferon (IFN...
|
|
WO/2024/056096A1 |
The present invention relates to a crystal form of a nitrogen-containing heterocyclic ketone compound and a preparation method therefor. Specifically, the present invention relates to a salt having a compound represented by general formu...
|
|
WO/2024/059668A2 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit epidermal growth factor receptor (EGFR), the methods of maki...
|
|
WO/2024/056909A1 |
The invention relates to the treatment of a viral infection, wherein an interferon lambda or its receptor is inhibited.
|
|
WO/2024/051843A1 |
A pharmaceutical composition for preventing and treating convalescent stage facial nerve paralysis and a use thereof. The pharmaceutical composition contains any one among or a combination of mannitol, sodium aescinate, acyclovir, valacy...
|
|
WO/2024/055003A1 |
The present disclosure relates generally to antibodies reactive with drug-peptide conjugates, as well as drug-peptide-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression v...
|
|
WO/2024/051852A1 |
The present invention relates to a pyrimidine-containing polycyclic biological inhibitor, a preparation method therefor, and use thereof. In particular, the present invention relates to a pyrimidine-containing polycyclic compound or a st...
|
|
WO/2024/054089A1 |
The present invention relates to novel camptothecin derivatives having the structures of chemical formulas 1 to 8 and carrier-drug conjugates including same, wherein the derivatives possess more desirable properties compared to existing ...
|
|
WO/2024/051792A1 |
A treatment method, comprising using a drug containing AST-3424, AST-3423 or AST-2870 and a salt thereof, an ester thereof, a solvate thereof, or an isotopic isomer thereof in combination with a drug containing cytarabine or daunorubicin...
|
|
WO/2024/051720A1 |
Disclosed in the present invention are a 5-pyridine-1H-indazole compound for targeted inhibition of CLK2 and a use of the compound. The compound of the present invention is a compound represented by formula (I), formula (II) or formula (...
|
|
WO/2024/054602A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions, and their use in treating disease, such as cancer.
|
|
WO/2024/055011A1 |
Formulations of substances comprising at least one RNA stabilizing substance and at least one substance comprising extracellular RNA or based on RNA and methods of using the formulations to improve the storage and use stability of substa...
|
|
WO/2024/052923A1 |
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.
|
|
WO/2024/052698A1 |
The present invention relates to compositions, in particular to lipid-based compositions that solubilise and/or encapsulate (sometimes high concentrations of) copper complex(es) (and/or derivatives or analogues thereof). Such lipid-based...
|
|
WO/2024/052895A1 |
This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of ...
|
|
WO/2024/052310A1 |
The present invention relates to a formulation, which comprises a fat-soluble vitamin and which can be used for fortifying early life nutrition products.
|
|
WO/2024/052766A1 |
A cytotoxic agent and its use in animal disbudding or for inhibiting horn growth in a juvenile animal. The cytotoxic agent can be a non-steroidal anti-inflammatory drug (NSAID) such as meloxicam or ketoprofen.
|
|
WO/2024/051749A1 |
Provided are a polymorph of a GLP-1R agonist compound I, a preparation method therefor, and use thereof. Compared with the free state of the compound I, the polymorph has higher stability and better processability, and is more suitable f...
|
|
WO/2024/052513A1 |
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...
|
|
WO/2024/052553A1 |
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditio...
|
|
WO/2024/051631A1 |
Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
|
|
WO/2024/054850A1 |
The present disclosure relates to RNA sequences, compositions, and methods of use to prevent viral replication, prevent RNA polymerase activity, activate innate immune responses, or combinations thereof.
|
|
WO/2024/054845A1 |
The present disclosure includes, among other things, compounds of formula I as CFTR modulators, pharmaceutical compositions, and methods of making and using the same.
|
|
WO/2024/055000A1 |
The invention includes lipid nanoparticles (LNP) capable of eliciting a modulated immune response against an antigen in a subject. The LNPs comprise: (a) at least one first nucleoside-modified ribonucleic acid (RNA) encoding an antigen; ...
|
|
WO/2024/051847A1 |
The present invention relates to a pharmaceutical composition for preventing and treating facial nerve micro-entrapment syndrome and a use thereof in the treatment of facial nerve micro-entrapment syndrome. The use comprises joint utiliz...
|
|
WO/2024/051835A1 |
Use of homovanillic acid and an analog thereof in the preparation of a drug for treating depression. Use of a substance Z in the preparation of a drug. The substance Z is a compound represented by formula I or a pharmaceutically acceptab...
|
|
WO/2024/051700A1 |
The present invention relates to a novel aryl ether substituted heterocyclic compound having GLP1R agonist activity. Specifically disclosed is a compound having a structure as represented by formula (I) as a GLP1R agonist, or a pharmaceu...
|
|
WO/2024/052700A1 |
A method for the preparation of a homogeneous nutritional or therapeutic composition comprising glutamine or glutamic acid, cystine, glycine and a selenium source comprises the steps of a) a serial dilution of the selenium source, b) mil...
|
|
WO/2024/051816A1 |
Provided is a bicyclic PRMT5 inhibitor, which is a compound having a structure represented by formula (I). Further provided are a preparation method for the compound and use of the compound in regulating PRMT5 activity or treating PRMT5-...
|
|
WO/2024/051354A1 |
Provided in the present application are a benzimidazole compound, and a preparation method therefor and the use thereof, wherein the benzimidazole compound has a structure as shown in formula A, has an effect of treating chronic heart fa...
|
|
WO/2024/051845A1 |
The present invention relates to a pharmaceutical composition for preventing and treating sequelae stage facial nerve paralysis. The pharmaceutical composition is selected from one among or a combination of mouse nerve growth factor, mon...
|
|
WO/2024/053320A1 |
Provided are: a type I collagen production promoter containing at least one of the compounds represented by any of structural formulae (1)-(4); and a bone strengthening agent.
|
